₹52.97
▼ -2.15 -3.90%
17 Jul 2026
NSE Listed
Krebs Biochemicals & Ind (KREBSBIO)
20-day avg volume: 11K shares
- Revenue fell 38% YoY.
- Company is loss-making at the latest annual result.
- Negative book value per share.
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹13 Cr | ₹13 Cr | ₹11 Cr | ₹6 Cr | ₹5 Cr | ₹4 Cr | ₹7 Cr | ₹7 Cr |
| EBITDA | ₹-4 Cr | ₹-4 Cr | ₹-6 Cr | ₹-7 Cr | ₹-4 Cr | ₹-4 Cr | ₹-1 Cr | ₹0 Cr |
| Net Profit | ₹-5 Cr | ₹-6 Cr | ₹-8 Cr | ₹-8 Cr | ₹-5 Cr | ₹-6 Cr | ₹-3 Cr | ₹-2 Cr |
| EPS | — | — | — | — | — | — | — | — |
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹34 Cr | ₹48 Cr | ₹34 Cr | ₹54 Cr | ₹61 Cr | ₹53 Cr | ₹51 Cr | ₹44 Cr |
| EBITDA | ₹-11 Cr | ₹-14 Cr | ₹-23 Cr | ₹-22 Cr | ₹-39 Cr | ₹-22 Cr | ₹-15 Cr | ₹-21 Cr |
| Net Profit | ₹-18 Cr | ₹-20 Cr | ₹-29 Cr | ₹-28 Cr | ₹-45 Cr | ₹-25 Cr | ₹-20 Cr | ₹-27 Cr |
| EPS | -12.97 | -15.46 | -17.9 | -14.37 | -20.81 | -11.3 | -9.15 | -12.49 |
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹142 Cr | ₹134 Cr | ₹159 Cr | ₹190 Cr | ₹175 Cr | ₹178 Cr | ₹169 Cr | ₹163 Cr |
| Total Liabilities | ₹157 Cr | ₹159 Cr | ₹202 Cr | ₹265 Cr | ₹274 Cr | ₹297 Cr | ₹315 Cr | ₹326 Cr |
| Equity | ₹-14 Cr | ₹-25 Cr | ₹-43 Cr | ₹-75 Cr | ₹-99 Cr | ₹-119 Cr | ₹-146 Cr | ₹-163 Cr |
| Total Debt | — | — | — | — | — | — | — | ₹225 Cr |
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | ₹-15 Cr | ₹-17 Cr | ₹-25 Cr | ₹2 Cr | ₹-8 Cr | ₹-2 Cr |
| Investing | ₹-23 Cr | ₹-23 Cr | ₹-13 Cr | ₹-8 Cr | ₹-5 Cr | ₹-4 Cr |
| Financing | ₹38 Cr | ₹40 Cr | ₹37 Cr | ₹6 Cr | ₹13 Cr | ₹6 Cr |
| Free Cash Flow | ₹-15 Cr | ₹-17 Cr | ₹-25 Cr | ₹2 Cr | ₹-8 Cr | ₹-5 Cr |
Healthcare · Drug Manufacturers - Specialty & Generic
Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. Krebs Biochemicals & Industries Limited was incorporated in 1991 and is based in Visakhapatnam, India.
krebsbiochem.com ↗As of 2026-06-30
Quarterly — figures in %. Latest 12 quarters.
| Period | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 72.7% | 72.7% | 72.7% | 72.7% | 72.7% | 72.7% | 72.7% | 72.7% | 72.7% | 72.7% | 72.7% | 72.7% |
| FIIs | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 26.8% | 26.8% | 26.8% | 26.8% | 26.8% | 26.8% | 26.8% | 26.8% | 26.8% | 26.8% | 26.8% | 26.8% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 9,030 | 8,990 | 8,909 | 8,848 | 9,425 | 9,091 | 8,798 | 9,118 | 8,912 | 8,710 | 8,553 | 8,521 |
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
| Name | Category | Stake | Shares |
|---|---|---|---|
| Ipca Laboratories Limited | Shareholding of Promoter and Promoter Group | 49.7% | 1.07 Cr |
| Hemalatha Ravi | Shareholding of Promoter and Promoter Group | 12.5% | 26,91,524 |
| Avinash Ravi | Shareholding of Promoter and Promoter Group | 9.9% | 21,40,272 |
| Sun Pharmaceutical Industries Ltd | Public Shareholding | 4.8% | 10,36,943 |
| Guttikonda Rajasekhar | Public Shareholding | 1.9% | 4,01,694 |
| Guttikonda Vara Lakshmi | Public Shareholding | 1.7% | 3,67,094 |
| Ajay Ravi | Shareholding of Promoter and Promoter Group | 0.5% | 1,12,997 |
| Dr R T Ravi | Shareholding of Promoter and Promoter Group | 0.1% | 23,474 |
| Aditya Ravi | Shareholding of Promoter and Promoter Group | 0.1% | 10,672 |
| Natwest Markets Plc | Public Shareholding | 0% | 522 |
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Dr R T Ravi | 0 | 0% | 2026-06-30 |
| Hemalatha Ravi | 0 | 0% | 2026-06-30 |
| Avinash Ravi | 0 | 0% | 2026-06-30 |
| Ajay Ravi | 0 | 0% | 2026-06-30 |
| Aditya Ravi | 0 | 0% | 2026-06-30 |
| Ipca Laboratories Limited | 0 | 0% | 2026-06-30 |
| Natwest Markets Plc | 0 | 0% | 2026-06-30 |
| Guttikonda Vara Lakshmi | 0 | 0% | 2026-06-30 |
| Guttikonda Rajasekhar | 0 | 0% | 2026-06-30 |
| Sun Pharmaceutical Industries Ltd | 0 | 0% | 2026-06-30 |
| Dr R T Ravi | 0 | 0% | 2026-03-31 |
| Hemalatha Ravi | 0 | 0% | 2026-03-31 |
| Name | Designation | Year |
|---|---|---|
| R T Ravi | Chairman & Non Executive Dir. | 2025 |
| Pabitra Bhattacharya | Non Independent Non Executive Director / MD | 2025 |
| Avinash Ravi | Non-Exec & Non-Independent Dir | 2025 |
| Popatlal M Kathariya | Independent Non Exe. Director | 2025 |
| Dipti Shah | Independent Non Exe. Director | 2025 |
| SATYA CHIGURUPATI | Independent Non Exe. Director | 2025 |
| Sumanth Karlapudi | Independent Non Exe. Director | 2025 |
| Manish Kumar Jain | Managing Director & CEO | 2025 |
| Rakesh R Kalbate | Company Sec. & Compli. Officer | 2025 |
| Segment | Revenue | Share |
|---|---|---|
| Pharma | ₹0 Cr | — |
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹10 | 23 | 22 | 22 |
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 0 | 0 | 0 | 0 | 0 | 71 |
| 2025 | 0 | 0 | 0 | 0 | 0 | 23 |
| 2025 | 0 | 0 | 0 | 0 | 0 | 2 |
📍 Kothapalli(V) Kasimkota(M), Anakapalli, Vishakapatnam, Andhra Pradesh, 531031
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search